We are live on ! Find out more
SGMO

SANGAMO THERAPEUTICS INC

Delisted

SGMO was delisted on the 4th of May, 2026.

134 hedge funds and large institutions have $61.3M invested in SANGAMO THERAPEUTICS INC in 2023 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 33 increasing their positions, 49 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

12% more call options, than puts

Call options by funds: $91K | Put options by funds: $81K

3.95% less ownership

Funds ownership: 61.65%57.7% (-4%)

12% less funds holding

Funds holding: 152134 (-18)

33% less repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 49

55% less capital invested

Capital invested by funds: $137M → $61.3M (-$76.1M)

65% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 26

Holders
134
Holders Change
-18
Holders Change %
-11.84%
% of All Funds
2.13%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
9
Increased
33
Reduced
49
Closed
26
Calls
$91K
Puts
$81K
Net Calls
+$10K
Net Calls Change
+$87K
Name Holding Trade Value Shares
Change
Change in
Stake
UBS Group
26
UBS Group
Switzerland
$448K +$695K +649,133 +670%
N
27
Nuveen
North Carolina
$430K -$2.97K -2,775 -0.4%
Mirae Asset Global Investments
28
Mirae Asset Global Investments
South Korea
$406K +$66.9K +62,465 +10%
GCP
29
GSA Capital Partners
United Kingdom
$336K -$265K -247,223 -31%
Bank of New York Mellon
30
Bank of New York Mellon
New York
$301K -$9.1K -8,499 -2%
Federated Hermes
31
Federated Hermes
Pennsylvania
$266K +$3.23K +3,013 +0.7%
Jacobs Levy Equity Management
32
Jacobs Levy Equity Management
New Jersey
$242K +$210K +195,734 +94%
Macquarie Group
33
Macquarie Group
Australia
$240K
Millennium Management
34
Millennium Management
New York
$226K -$579K -541,021 -59%
Tudor Investment Corp
35
Tudor Investment Corp
Connecticut
$218K
Wells Fargo
36
Wells Fargo
California
$195K -$24K -22,402 -6%
Group One Trading
37
Group One Trading
Illinois
$185K +$204K +190,465 +162%
BCM
38
Bridgeway Capital Management
Texas
$177K +$316K +295,000 New
Fidelity Investments
39
Fidelity Investments
Massachusetts
$172K -$2.62K -2,445 -0.8%
William Blair & Company
40
William Blair & Company
Illinois
$165K -$21.4K -20,000 -7%
Prudential Financial
41
Prudential Financial
New Jersey
$162K -$125K -116,400 -30%
T. Rowe Price Associates
42
T. Rowe Price Associates
Maryland
$160K +$37.8K +35,290 +15%
AllianceBernstein
43
AllianceBernstein
Tennessee
$152K
RhumbLine Advisers
44
RhumbLine Advisers
Massachusetts
$129K +$3.38K +3,159 +1%
Massachusetts Financial Services
45
Massachusetts Financial Services
Massachusetts
$119K -$8.13K -7,597 -4%
Invesco
46
Invesco
Georgia
$111K +$5.99K +5,597 +3%
BNP Paribas Financial Markets
47
BNP Paribas Financial Markets
France
$104K +$77.2K +72,108 +71%
GSEP
48
Golden State Equity Partners
California
$99.7K +$32.7K +30,500 +22%
Barclays
49
Barclays
United Kingdom
$87.2K -$21.1K -19,668 -12%
Royal Bank of Canada
50
Royal Bank of Canada
Ontario, Canada
$84K -$96K -89,665 -39%

SGMO Hedge Fund Activity: Q3 2023 in Review

134 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in SANGAMO THERAPEUTICS INC (SGMO) for Q3 2023, worth a combined $61.3M — down 55% from $137M a quarter earlier.

Sellers outnumbered buyers: 26 funds closed out of SGMO and 9 opened new positions — a net loss of 17 holders — while 49 trimmed existing stakes and 33 added.

The largest buyer was Wasatch Advisors, adding an estimated $1M. The largest seller was Globeflex Capital, exiting entirely with an estimated $907K sold.

  • 134 institutional investors held SANGAMO THERAPEUTICS INC (SGMO) as of Q3 2023, down from 152 in Q2 2023.
  • Funds reported $61.3M of SANGAMO THERAPEUTICS INC stock for Q3 2023, down 55% quarter-over-quarter.
  • 9 funds opened new SANGAMO THERAPEUTICS INC positions in Q3 2023 and 26 closed out, a net change of -17 holders.
  • The largest SANGAMO THERAPEUTICS INC buyer in Q3 2023 was Wasatch Advisors, an estimated $1M added.
  • The largest SANGAMO THERAPEUTICS INC seller in Q3 2023 was Globeflex Capital, an estimated $907K sold.

Based on aggregated 13F filings for Q3 2023.